Hydroxylation of antitubercular drug candidate, sq109, by mycobacterial cytochrome p450

Sergey Bukhdruker, Tatsiana Varaksa, Irina Grabovec, Egor Marin, Polina Shabunya, Maria Kadukova, Sergei Grudinin, Anton Kavaleuski, Anastasiia Gusach, Andrei Gilep, Valentin Borshchevskiy, Natallia Strushkevich

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Spreading of the multidrug‐resistant (MDR) strains of the one of the most harmful pathogen Mycobacterium tuberculosis (Mtb) generates the need for new effective drugs. SQ109 showed activity against resistant Mtb and already advanced to Phase II/III clinical trials. Fast SQ109 degradation is attributed to the human liver Cytochrome P450s (CYPs). However, no information is available about interactions of the drug with Mtb CYPs. Here, we show that Mtb CYP124, previously assigned as a methyl‐branched lipid monooxygenase, binds and hydroxylates SQ109 in vitro. A 1.25 Å‐resolution crystal structure of the CYP124–SQ109 complex unambiguously shows two conformations of the drug, both positioned for hydroxylation of the ω‐methyl group in the trans position. The hydroxylated SQ109 presumably forms stabilizing H‐bonds with its target, Mycobacterial membrane protein Large 3 (MmpL3). We anticipate that Mtb CYPs could function as analogs of drug‐metabolizing human CYPs affecting pharmacokinetics and pharmacodynamics of antitubercular (anti‐TB) drugs.

Original languageEnglish
Article number7683
Pages (from-to)1-15
Number of pages15
JournalInternational Journal of Molecular Sciences
Issue number20
Publication statusPublished - 2 Oct 2020


  • Crystal structure
  • CYP124
  • Cytochrome P450
  • Mycobacterium tuberculosis
  • SQ109


Dive into the research topics of 'Hydroxylation of antitubercular drug candidate, sq109, by mycobacterial cytochrome p450'. Together they form a unique fingerprint.

Cite this